Use of Ziv Aflibercept in Different Retinal Diseases

• Status: Completed
• Trial end date: 2020-01-01
• Target enrollment: 0
• Participant gender: All

Summary

A prospective interventional case series study was conducted on 20 eyes of 20 patients with active myopic choroidal neovascularisation (CNV) ,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic central retinal vein occlusion(CRVO) after approval of the Ethical Committee of the Faculty of Medicine, Tanta University . All procedures were carried out under the tenets of the Helsinki Declaration. Written consent was provided by all participants after discussing the procedure, alternative treatment plans, follow-up schedules, and possible benefits and risks.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Amin El Sayed Nawar
• Collaborator: Tanta University
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• The study included treatment naive patients suffering from recently diagnosed active myopic subfoveal or juxtafoveal CNV less than 2 months documented by fundus fluorescein angiography (FFA)and optical coherence tomography (OCT ) , pathological myopia more than 6 D was included .

Exclusion Criteria:

• Previous intraocular surgery .

• Coincident retinal pathology as diabetic retinopathy, retinal vein occlusion .

• CNV due to other causes like age related macular degeneration ,angioid streaks,trauma and choroiditis.

• Extrafoveal myopic CNV .

• Patients received other lines of treatment for CNV like photodynamic therapy ,laser photocoagulation or intravitreal injection of triamcinolone or other anti VEGF(vascular endothelial growth factor) agents.

• Known glaucoma , clinical suspicion of glaucoma or IOP(intraocular pressure) more than 20 mmHg.

• Prior ocular inflammation.

• The presence of retinal degeneration.

• Patients who didnot complete 6 months of follow up